Does the use of SSRIs reduce medical care utilization and expenditures?

Journal of Mental Health Policy and Economics

Volumn 8, Issue 3, 2005, Pages 119-129

  Chung, Sukyung ^a  

^a IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DATA ANALYSIS; DEPRESSION; DISEASE SEVERITY; DRUG INDICATION; DRUG USE; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEALTH STATUS; HEALTH SURVEY; HOSPITAL CARE; HOSPITAL PATIENT; HUMAN; LINEAR SYSTEM; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL DECISION MAKING; OUTPATIENT CARE; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHIATRIC DIAGNOSIS; REGRESSION ANALYSIS; RESOURCE MANAGEMENT; SAMPLING; SOCIOECONOMICS; STATISTICAL MODEL; SYMPTOMATOLOGY;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEMOGRAPHY; DRUG UTILIZATION; FEMALE; HEALTH CARE SURVEYS; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; MALE; MENTAL DISORDERS; MENTAL HEALTH SERVICES; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 26944440841     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Centers for Medicare and Medicaid Services (CMS), Office of the Actuary, National Health Statistics Group, available at www.cms.hhs.gov, accessed November 20, 2002.
2. Langreth R. High anxiety: rivals threaten Prozac. Wall St J 1996;9:B1-B2.
3. Glaser M. Annual Rx survey. Drug Top 1997; 141: 45-53.
4. Drug Topics Red Book. Montvale, N.J.: Medical Economics, 2000.
5. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995; 310: 1433-1438.
6. Montgomery SA, Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int clin Psychopharmacol 1995; 9: 33-40.
7. Mulrow CD, Williams JW, Trivedi M, Chiquette E, Aguilar C, Cornell JE, Badgett R, Noel PH, Lawrence V, Lee S, Luther M, Ramirez G, Richardson WS, Stamm K. Treatment of depression: newer pharmacotherapies. Evidence Report/Technology Assessment No.7. AHCPR Publication No.99-E014. Rockville, MD: Agency for Health Care Policy and Research, February 1999.
8. McCombs JS, Nichol MB, Stimmel GL, Sclar DA, Beasley CM Jr, Gross LS. The cost of antidepressant drug therapy failure: A study of antidepressant use patterns in a Medicaid Population. J Clin Psychiatry 1990; 51: 60-69.
9. National Health Accounts, Center for Medicare and Medicaid Services, Office of the Actuary, National Health Statistics Group, January 2000, available at http://www.cms.hhs.gov/statistics/nhe, accessed September 7, 2003.
10. Hylan TR, Crown WH, Meneades L, Heiligenstein JH, Melfi CA, Croghan TW, Buesching DP. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis. J Affect Disord 1998; 48: 125-133.
11. McCombs JS, Nichol MB, Stimmel GL. The role of SSRI antidepressants for treating depressed patients in the California Medicaid (Medi-Cal) program. Value Health 1999; 2: 269-280.
12. Sclar DA, Skaer TL, Robison LM, Galin RS, Legg RF, Nemec NL. Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis. J Clin Psychiatry 1998; 59: 13-17.
13. Thompson D, Hylan TR, McMullen W, Romeis ME, Buesching D, Oster G. Predictors of a medical-offset effect among patients receiving antidepressant therapy. Am J Psychiatry 1998; 155: 824-827.
14. Simon GE, Fishman P. Cost implications of initial antidepressant selection in primary care. Pharmacoeconomics 1998; 13: 61-70.
15. Bentkover JD, Feighner JP. Cost analysis of paroxetine versus imipramine in major depression. Pharmacoeconomics 1995; 8: 223-332.
16. Einarson TR, Arikian S, Sweeney S, Doyle J. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther 1995; 17: 136-153.
17. Revicki DA, Brown RE, Keller MB, Gonzales J, Culpepper L, Hates RE. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry 1997; 58: 47-58.
18. LaPierre Y, Bentkover J, Schainbaum S, Manners S. Direct cost of depression; analysis of treatment costs of paroxetine versus imipramine in Canada. Can J Psychiatry 1995; 40: 370-377.
19. Hutchins DS, Klein EG, Signa WF, Young CH, Gregor KJ. Selective serotonin reuptake inhibitor utilization patterns: consistency across research designs. Clin Ther 1998; 20: 797-805.
20. Poisal, J, Chulis, G. Medicare beneficiaries and drug coverage. Health Affairs 2000; 19: 248-256.
21. Conner TM, Crismon ML, Still DJ. A critical review of selected pharmacoeconomic analyses of antidepressant therapy. Ann Pharmacother 1999; 33: 364-372.
22. Halpern MT, Luce BR, Brown RE, Geneste B. Health and economic outcomes modeling practices: a suggested framework. Value Health 1998; 1: 131-147.
23. Halpern MT, McKenna M, Hutton J. Modeling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217-227.
24. Depression Guideline Panel. Depression in primary care. Vol. 2, Treatment of major depression. Clinical Practice Guideline, No. 5. AHCPR Publication No. 93-0551. Rockville, MD: US DHHS, AHCPR, 1993.
25. Hylan TR, Kotsanos JG, Andersen JS, Brown SH, Copley-Merrimam C, Egbuonu-Davis L, Heiligenstein JH, Overhage JM, Whiteside RE. Comparison of a decision analytic model with results from a naturalistic economic clinical trial: an application to evaluating alternative antidepressants. Am J Manag Care 1996; 2: 1211-1223.
26. Harrington C, Gregorian R, Gemmen, E. 2000. Chapter 6. Pharmacoeconomics of Newer Antidepressant and Antipsychotic Medications in Access and Utilization of New Antidepressant and Antipsychotic Medications, The Lewin Group, availableat//aspe.hhs.gov/health/reports/Psychmedaccess/chap07.htm, accessed November 10, 2004.
27. Revicki DA, Frank L. Pharmacoeconomic evaluation in the real world: effectiveness versus efficacy studies. Pharmacoeconomics 1999; 15: 423-434.
28. Drummond MF, Davies LM. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care 1991; 7: 561-573.
29. Medical Expenditure Panel Survey, AHRQ, available at http://www.ahrq.gov/data/mepsix.htm, accessed September 7, 2003.
30. Machlin SR, Dougherty DD. Overview of Methodology for Imputing Missing Expenditure Data in the Medical Expenditure. AHRQ Working Papers #04003 December 2004, Rockville, MD
31. Consumer Price Index-Urban, Bureau of Labor Statistics, US Department of Labor, www.bls.gov/cpi/home.htm, accessed October 11, 2004.
32. AHRQ, Center for Organization and Delivery Studies, Healthcare Cost and Utilization Project (HCUP), http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp, accessed November 10, 2004.
33. Sleath B, Shih YC. Sociological influences on antidepressant prescribing. Soc Sci Med 2003; 56: 1335-1344.
34. Reichert S, Simon T, Halm E. Physicians' attitudes about prescribing and knowledge about the cost of common medications. Arch Intern Med 2000; 160: 2799-2803.
35. Melfi CA, Croghan TW, Hanna MP, Robinson RL. Racial variation in antidepressant treatment in Medicaid population. J Clin Psychiatry 2000; 61: 16-21.
36. Bartels SJ, Horn S, Sharkey P, Levine K. Treatment of depression in older primary care patients in health maintenance organizations. Int J Psychiatry Med 1997; 27: 215-231.
37. Mosby's Drug Consult - 14th Ed. (2004) Mosby, Inc., 2004, available at STAT!Ref Online Electronic Medical Library: http://online.statrefcom.libproxy.lib.unc.edu/document.aspx?fxid= 26&docid=1, accessed June 23,2004.
38. Domino ME, Salkever DS. Price elasticity and pharmaceutical selection: the influence of managed care. Health Econ 2003; 2: 565-586.
39. Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Can Med Assoc J 1998; 159: 1245-1252.
40. Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med 2000; 343: 1942-1950.
41. Box G, Cox D. An analysis of transformations. J R Stat Soc 1964: 211-252.
42. Wooldridge JM. A simple specification test for the predictive ability of transformation models. Rev Econ Stat 1994; 76(1): 59-65.
43. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 2000; 17:283-295.
44. Duan N. Smearing Estimate: A Nonparametric Retransformation Method. J Am Stat Assoc 1983; 78: 605-610.
45. Breusch TS, Pagan AR. The Lagrange multiplier test and its applications to model-specification in econometrics. Rev Econ Stud 1980; 47(1): 239-253.
46. Cook RD, Weisberg S. Diagnostics for heteroscedasticity in regression. Biometrika 1983; 70(1): 1-10.
47. Ai C, Norton EC. Standard errors for the retransformation problem with heteroscedasticity. J Health Econ 2000; 19: 697-718.
48. Powers RH, Kniesner TJ, Croghan TW. Psychotherapy and pharmacotherapy in depression. J Ment Health Policy Econ 2002; 5: 153-161.
49. Del Bocca FK, Noll JA. Collecting valid data from community sources - truth or consequences: the validity of self-report in health services research on addictions. Addictions 2000; 95: 347-360.
50. Reijneveld SA, Stronks K. The validity of self-reported use of health care across socioeconomic strata: a comparison of survey and registration data. Int J Epidemiol 2001; 30: 1407-1414.
51. Langenbucher J, Merrill J. The validity of self-reported cost events by substance abusers. Limits, liabilities, and future directions. Eval Rev 2001; 25: 184-210.
52. Cox B, Iachan RA. Comparison of Household and Provider Reports of Medical Conditions. J Am Stat Assoc 1987; 82(400): 1013-1018.
53. Simon GE, VonKorff M, Heiligenstein JH. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs. tricyclic antidepressants. JAMA 1996; 275: 1897-1902.
54. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003; 60(8): 1284-1289.
55. Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry 2001; 13(1): 31-41.
56. Warrington SJ, Padgham C, Lader M. The cardiovascular effects of antidepressants. Psychol Med Monogr Suppl 1989; 16: 1-40.